Biomedical subjects

K Capel-Edwards

Publications and source records attributed to K Capel-Edwards.

10 recordsLinked to original sources

PubMed1989

Ondansetron: pre-clinical safety evaluation.

A programme of pre-clinical safety evaluation of ondansetron has been undertaken which involved a series of studies - single dose studies, repeat dose studies, reproduction studies, genotoxicity studies, oncogenicity studies, local irritancy studies, and a hypersensitivity study. Ondansetron was found to have a very good safety profile, and the only toxicity identified was associated with central nervous system activity when near lethal doses were administered. It was not genotoxic and had no reproductive or oncogenic potential.

Administration, Oral↗

PubMed1981

The effect of controlled daily blood loss on the haemoglobin concentration, erythrocyte count and reticulocyte count of male rats.

0.2, 0.6 or 1 ml of blood was removed from rats once daily on 17 consecutive days. Haemoglobin concentration and erythrocyte counts fell rapidly until day 7 or 9 and were reflected after day 2 by an increase in reticulocytes. From 9 to 17 there was little further change and 14 days after the last bleed the haematological results were within the normal range. The increase in haemoglobin production correlated well with the increase in reticulocyte numbers.

Animals↗

PubMed1980

Effect of timing of cefuroxime dosage on its protection of rats against gentamicin nephrotoxicity.

The neophrotoxic effect on rats of once daily treatment with 40 or 45 mg gentamicin/kg/day for ten days was substantially reduced by administration of 4 g cefuroxime/kg/day, either at the same time or eight hours later. This dosage of cefuroxime was protective when given for only two consecutive days starting on the first to third days of gentamicin treatment, but enhanced gentamicin nephrotoxocity when started on the sixth or subsequent days.

Animals↗

PubMed1979

Toxicological studies on cefuroxime sodium.

The intravenous LD50 of cefuroxime sodium for mice was 10.4 g/kg. The maximum dosage administered in other acute toxicity tests was well tolerated by mice (10 g/kg, subcutaneous), by rats (4 g/kg, intravenous, 5 g/kg, subcutaneous) and by cats, dogs and monkeys (2 g/kg, intramuscularly). Cefuroxime sodium was administered subcutaneously (s.c.) or intramuscularly (i.m.) for 3 months to rats (100, 300 or 900 mg/kg/day) followed by a recovery period, and also for 6 months to rats and dogs (50, 150 or 450 mg/kg/day) and for 1 month to monkeys (150 or 450 mg/kg/day). In all these tests there were no serious toxic effects. Minor haematological changes were attributable in part if not entirely to haemorrhage and tissue reaction at the site of injection of large doses. In rats large doses caused some increase in urine volume and electrolyte excretion, and slightly aggravated an age related nephropathy. Administration to rats intravenously (i.v.) for1 month of up to 400 mg/kg/day had no toxic effects. In reproduction studies on mice and rabbits there were no adverse effects on fertility, organogenesis or the rearing of young.

Animals↗

PubMed1977